Docetaxel in the management of head and neck cancer

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Squamous cell carcinoma of the head and neck is a major health problem, and much effort is being made in the different settings of its presentation. Much of the recent progress has been made in locoregionally advanced inoperable disease, mainly with the optimal combination of concurrent chemoradiotherapy and with the introduction of new active drugs, such as docetaxel, in the induction phase of the treatment. The association of docetaxel, cisplatin, and 5-fluorouracil (TPF) regimen is now acknowledged as being the gold standard of induction treatment. The subset of patients with recurrent/metastatic disease still carries a grim prognosis. For the time being, new biological therapies have not dramatically changed this scenario, even in combination with conventional treatments. Little is known about the role of docetaxel and, in general, of chemotherapy in the adjuvant setting, even though it is increasingly acknowledged that, beyond a certain risk, concurrent adjuvant chemoradiotherapy is required. The main aim of the research on head and neck cancer probably lies in the identification of biomolecular markers that are able to predict clinical behaviour, thus allowing appropriate treatment tailoring. The identification of human papilloma virus infection as the agent of a particular form of oropharyngeal cancer is an example of this strategy in consideration of the peculiar characteristics.

Original languageEnglish
Pages (from-to)639-645
Number of pages7
JournalAnti-Cancer Drugs
Volume20
Issue number8
DOIs
Publication statusPublished - 2009

Fingerprint

docetaxel
Head and Neck Neoplasms
Chemoradiotherapy
Papillomaviridae
Adjuvant Chemoradiotherapy
Oropharyngeal Neoplasms
Biological Therapy
Virus Diseases
Therapeutics
Adjuvant Chemotherapy
Fluorouracil
Cisplatin
Health
Research
Pharmaceutical Preparations

Keywords

  • Concurrent chemoradiotherapy
  • Docetaxel
  • Head and neck cancer
  • Induction chemotherapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research
  • Oncology

Cite this

Docetaxel in the management of head and neck cancer. / Caponigro, Francesco; Longo, Francesco; Perri, Francesco; Ionna, Franco.

In: Anti-Cancer Drugs, Vol. 20, No. 8, 2009, p. 639-645.

Research output: Contribution to journalArticle

@article{af3f0dd704e0450eb781d4ec4520808f,
title = "Docetaxel in the management of head and neck cancer",
abstract = "Squamous cell carcinoma of the head and neck is a major health problem, and much effort is being made in the different settings of its presentation. Much of the recent progress has been made in locoregionally advanced inoperable disease, mainly with the optimal combination of concurrent chemoradiotherapy and with the introduction of new active drugs, such as docetaxel, in the induction phase of the treatment. The association of docetaxel, cisplatin, and 5-fluorouracil (TPF) regimen is now acknowledged as being the gold standard of induction treatment. The subset of patients with recurrent/metastatic disease still carries a grim prognosis. For the time being, new biological therapies have not dramatically changed this scenario, even in combination with conventional treatments. Little is known about the role of docetaxel and, in general, of chemotherapy in the adjuvant setting, even though it is increasingly acknowledged that, beyond a certain risk, concurrent adjuvant chemoradiotherapy is required. The main aim of the research on head and neck cancer probably lies in the identification of biomolecular markers that are able to predict clinical behaviour, thus allowing appropriate treatment tailoring. The identification of human papilloma virus infection as the agent of a particular form of oropharyngeal cancer is an example of this strategy in consideration of the peculiar characteristics.",
keywords = "Concurrent chemoradiotherapy, Docetaxel, Head and neck cancer, Induction chemotherapy",
author = "Francesco Caponigro and Francesco Longo and Francesco Perri and Franco Ionna",
year = "2009",
doi = "10.1097/CAD.0b013e32832c9c51",
language = "English",
volume = "20",
pages = "639--645",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Docetaxel in the management of head and neck cancer

AU - Caponigro, Francesco

AU - Longo, Francesco

AU - Perri, Francesco

AU - Ionna, Franco

PY - 2009

Y1 - 2009

N2 - Squamous cell carcinoma of the head and neck is a major health problem, and much effort is being made in the different settings of its presentation. Much of the recent progress has been made in locoregionally advanced inoperable disease, mainly with the optimal combination of concurrent chemoradiotherapy and with the introduction of new active drugs, such as docetaxel, in the induction phase of the treatment. The association of docetaxel, cisplatin, and 5-fluorouracil (TPF) regimen is now acknowledged as being the gold standard of induction treatment. The subset of patients with recurrent/metastatic disease still carries a grim prognosis. For the time being, new biological therapies have not dramatically changed this scenario, even in combination with conventional treatments. Little is known about the role of docetaxel and, in general, of chemotherapy in the adjuvant setting, even though it is increasingly acknowledged that, beyond a certain risk, concurrent adjuvant chemoradiotherapy is required. The main aim of the research on head and neck cancer probably lies in the identification of biomolecular markers that are able to predict clinical behaviour, thus allowing appropriate treatment tailoring. The identification of human papilloma virus infection as the agent of a particular form of oropharyngeal cancer is an example of this strategy in consideration of the peculiar characteristics.

AB - Squamous cell carcinoma of the head and neck is a major health problem, and much effort is being made in the different settings of its presentation. Much of the recent progress has been made in locoregionally advanced inoperable disease, mainly with the optimal combination of concurrent chemoradiotherapy and with the introduction of new active drugs, such as docetaxel, in the induction phase of the treatment. The association of docetaxel, cisplatin, and 5-fluorouracil (TPF) regimen is now acknowledged as being the gold standard of induction treatment. The subset of patients with recurrent/metastatic disease still carries a grim prognosis. For the time being, new biological therapies have not dramatically changed this scenario, even in combination with conventional treatments. Little is known about the role of docetaxel and, in general, of chemotherapy in the adjuvant setting, even though it is increasingly acknowledged that, beyond a certain risk, concurrent adjuvant chemoradiotherapy is required. The main aim of the research on head and neck cancer probably lies in the identification of biomolecular markers that are able to predict clinical behaviour, thus allowing appropriate treatment tailoring. The identification of human papilloma virus infection as the agent of a particular form of oropharyngeal cancer is an example of this strategy in consideration of the peculiar characteristics.

KW - Concurrent chemoradiotherapy

KW - Docetaxel

KW - Head and neck cancer

KW - Induction chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=70349332937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349332937&partnerID=8YFLogxK

U2 - 10.1097/CAD.0b013e32832c9c51

DO - 10.1097/CAD.0b013e32832c9c51

M3 - Article

C2 - 19639668

AN - SCOPUS:70349332937

VL - 20

SP - 639

EP - 645

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 8

ER -